HK1197186A1 - Method for treating or preventing a pancreatic dysfunction - Google Patents

Method for treating or preventing a pancreatic dysfunction

Info

Publication number
HK1197186A1
HK1197186A1 HK14110752A HK14110752A HK1197186A1 HK 1197186 A1 HK1197186 A1 HK 1197186A1 HK 14110752 A HK14110752 A HK 14110752A HK 14110752 A HK14110752 A HK 14110752A HK 1197186 A1 HK1197186 A1 HK 1197186A1
Authority
HK
Hong Kong
Prior art keywords
treating
preventing
pancreatic dysfunction
dysfunction
pancreatic
Prior art date
Application number
HK14110752A
Other languages
English (en)
Chinese (zh)
Inventor
．伊泰斯庫
．克里希南
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of HK1197186A1 publication Critical patent/HK1197186A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/66—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/62—Insulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
HK14110752A 2008-11-20 2014-10-27 Method for treating or preventing a pancreatic dysfunction HK1197186A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US19979608P 2008-11-20 2008-11-20

Publications (1)

Publication Number Publication Date
HK1197186A1 true HK1197186A1 (en) 2015-01-09

Family

ID=42197754

Family Applications (2)

Application Number Title Priority Date Filing Date
HK14110752A HK1197186A1 (en) 2008-11-20 2014-10-27 Method for treating or preventing a pancreatic dysfunction
HK16111604.7A HK1223396A1 (zh) 2008-11-20 2016-10-05 用於治療或預防胰功能異常的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK16111604.7A HK1223396A1 (zh) 2008-11-20 2016-10-05 用於治療或預防胰功能異常的方法

Country Status (11)

Country Link
US (3) US8894972B2 (xx)
EP (2) EP3002329B1 (xx)
JP (6) JP5891034B2 (xx)
KR (2) KR101832497B1 (xx)
CN (3) CN104546912B (xx)
AU (1) AU2009317874B2 (xx)
CA (1) CA2744228C (xx)
DK (1) DK2350266T3 (xx)
ES (2) ES2651503T3 (xx)
HK (2) HK1197186A1 (xx)
WO (1) WO2010057260A1 (xx)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2651503T3 (es) 2008-11-20 2018-01-26 Mesoblast, Inc. Método para tratar o prevenir una disfunción pancreática
PL2403605T3 (pl) 2009-03-05 2016-01-29 Harvard College Kompozycje zawierające przeciwciało specyficzne względem aP2 albo jego fragment do zastosowania w leczeniu cukrzycy, nietolerancji glukozy lub insulinooporności wywołanej otyłością
ES2831259T3 (es) * 2010-07-02 2021-06-08 Mesoblast Inc Tratamiento de la enfermedad de injerto contra huésped
CA2836488C (en) * 2011-05-19 2021-10-26 Mesoblast, Inc. Methods for treating obesity and/or metabolic syndrome
SG195127A1 (en) * 2011-06-03 2013-12-30 Mesoblast Inc Methods of treating or preventing neurological diseases
AU2012278925B2 (en) * 2011-07-04 2016-05-19 Mesoblast, Inc. Methods of treating or preventing rheumatic disease
AU2012279995C1 (en) 2011-07-06 2019-10-24 Cell Therapy Limited Progenitor cells of mesodermal lineage
CN104098682B (zh) * 2013-04-03 2018-01-02 苏州偲聚生物材料有限公司 多肽、包含该多肽的检测器件和检测试剂盒
EP3556850A1 (en) * 2012-12-12 2019-10-23 Mesoblast, Inc. Treatment of diseases of endothelial dysfunction and inflammation
US20140314872A1 (en) * 2013-04-22 2014-10-23 Hans Klingemann Methods of Use of Culture Supernatant Obtained from Mesenchymal Stem Cells from Dogs and Cats for Treatment of Organ Dysfunction
CN104714021B (zh) * 2013-12-12 2016-05-25 张曼 尿液凝血酶原蛋白在2型糖尿病合并冠心病中的应用
TW201702271A (zh) 2015-04-30 2017-01-16 哈佛大學校長及研究員協會 治療代謝病症之抗－ａｐ２抗體及抗原結合劑
EP3475299A4 (en) * 2016-06-27 2020-03-18 President and Fellows of Harvard College COMPOUNDS USEFUL FOR TREATING METABOLIC DISORDERS
CA3066733A1 (en) 2017-06-09 2018-12-13 President And Fellows Of Harvard College Method to identify compounds useful to treat dysregulated lipogenesis, diabetes, and related disorders
CN110959579A (zh) * 2019-11-14 2020-04-07 顾隽 患者来源的淋巴瘤免疫缺陷小鼠移植瘤模型的构建方法及其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
WO1992001070A1 (en) 1990-07-09 1992-01-23 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce High efficiency packaging of mutant adeno-associated virus using amber suppressions
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
CA2115742A1 (en) 1991-08-20 1993-03-04 Ronald G. Crystal Adenovirus mediated transfer of genes to the gastrointestinal tract
AU2003901668A0 (en) 2003-03-28 2003-05-01 Medvet Science Pty. Ltd. Non-haemopoietic precursor cells
AUPQ147799A0 (en) 1999-07-07 1999-07-29 Medvet Science Pty. Ltd. Mesenchymal precursor cell
DE19939781C2 (de) 1999-08-21 2003-06-18 Schott Glas Skulltiegel für das Erschmelzen oder das Läutern von anorganischen Substanzen, insbesondere von Gläsern und Glaskeramiken
WO2004016747A2 (en) * 2002-08-14 2004-02-26 University Of Florida Bone marrow cell differentiation
US9631176B2 (en) * 2003-11-04 2017-04-25 Biomaster, Inc. Method for preparing stem cells from fat tissue
EP1807510A4 (en) * 2004-09-24 2008-01-23 Angioblast Systems Inc MEMP (MULTIPOTENTIAL EXPANDED MESENCHYMAL PRECURSOR CELL PROGENY) AND USES THEREOF
KR101446634B1 (ko) * 2005-04-12 2014-10-16 메소블라스트, 아이엔씨. 조직 비특이적인 알카리 포스파타제에 의한 다분화성 성체세포의 분리
GB0514785D0 (en) * 2005-07-19 2005-08-24 Innovia Films Ltd Sealed ream wrap package and films suitable for forming such packages
JP2009535347A (ja) * 2006-04-28 2009-10-01 テュレーン・ユニバーシティ・ヘルス・サイエンシーズ・センター 糖尿病の治療方法
US20100247491A1 (en) * 2007-02-01 2010-09-30 Christof Westenfelder Potentiation of Stem Cell Homing and Treatment of Organ Dysfunction or Organ Failure
ES2651503T3 (es) 2008-11-20 2018-01-26 Mesoblast, Inc. Método para tratar o prevenir una disfunción pancreática
US9405700B2 (en) 2010-11-04 2016-08-02 Sonics, Inc. Methods and apparatus for virtualization in an integrated circuit

Also Published As

Publication number Publication date
JP2020011972A (ja) 2020-01-23
JP2017214384A (ja) 2017-12-07
KR102011609B1 (ko) 2019-08-16
JP7051770B2 (ja) 2022-04-11
ES2651503T3 (es) 2018-01-26
JP2015205894A (ja) 2015-11-19
CA2744228C (en) 2018-06-19
CN104546912A (zh) 2015-04-29
ES2550795T3 (es) 2015-11-12
EP2350266B1 (en) 2015-07-29
JP6499016B2 (ja) 2019-04-10
AU2009317874B2 (en) 2016-04-21
CN102307992B (zh) 2015-01-07
US20110243902A1 (en) 2011-10-06
EP3002329A1 (en) 2016-04-06
CN103800370B (zh) 2017-10-24
JP5891034B2 (ja) 2016-03-22
US20170042945A1 (en) 2017-02-16
JP2012509283A (ja) 2012-04-19
JP2022031662A (ja) 2022-02-22
EP3002329B1 (en) 2017-08-16
CN104546912B (zh) 2019-11-08
US8894972B2 (en) 2014-11-25
WO2010057260A1 (en) 2010-05-27
DK2350266T3 (en) 2015-11-02
US9968640B2 (en) 2018-05-15
CN102307992A (zh) 2012-01-04
KR20110095875A (ko) 2011-08-25
US9480713B2 (en) 2016-11-01
CA2744228A1 (en) 2010-05-27
JP2023116536A (ja) 2023-08-22
KR20180021230A (ko) 2018-02-28
CN103800370A (zh) 2014-05-21
EP2350266A1 (en) 2011-08-03
AU2009317874A1 (en) 2010-05-27
KR101832497B1 (ko) 2018-02-26
HK1223396A1 (zh) 2017-07-28
US20150064148A1 (en) 2015-03-05
EP2350266A4 (en) 2013-03-06

Similar Documents

Publication Publication Date Title
HK1223396A1 (zh) 用於治療或預防胰功能異常的方法
IL257418A (en) Methods for treating addiction
EP2137280A4 (en) METHOD FOR TREATING A FRACTURED FORMATION
GB2456111B (en) Method for treating a subterranean formation
EP2019675A4 (en) METHODS FOR TREATING OR PREVENTING NEOPLASIA
EP2134806A4 (en) METHOD FOR TREATING A CARBON HYDROGEN INFORMATION
EP2188299A4 (en) METHOD FOR TREATING DIABETES
EP2139933A4 (en) METHOD FOR TREATING FORMATION WITH A SOLVENT
SI2260150T1 (sl) Postopek preprečitve padca skal
GB0813278D0 (en) Method for inhibiting corrosion
EP1987110A4 (en) METHOD OF SUBSTRATE TREATMENT
PL2301893T3 (pl) Sposób oczyszczania ścieku
PT2096102E (pt) Processo para a produção de metileno-difenil-diisocianatos
EP2236467A4 (en) PROCESS FOR SLUDGE DRYING
EP2299822A4 (en) METHOD FOR TREATING NEURODEGENERATIVE DYSFUNCTION
AP2010005522A0 (en) A method of treating a sulphide mineral.
PL2376597T3 (pl) Proces obróbki odpadów
PL2441462T3 (pl) Sposób leczenia cukrzycy typu I
PT2393758E (pt) Processo de tratamento de águas residuais
EP2231150A4 (en) METHOD FOR SEARCH TREATMENT WITH CROSS-COMPOSITE COMPOSITIONS
ZA200904282B (en) Method for manufacturing an austenitic steel object
ZA200903900B (en) Method for treating ligno-cellulosic materials
EP2296461A4 (en) METHODS OF TREATING ARTHROPODS
GB2453912B (en) Method for treating spent pot liner
PT2509599E (pt) Processo para o tratamento de cancro pancreático